A Single Intravitreal Injection of Ranibizumab Provides No Neuroprotection in a Nonhuman Primate Model of Moderate-to-Severe Nonarteritic Anterior Ischemic Optic Neuropathy | Zendy

Neil R. Miller | Zendy; Mary A. Johnson | Zendy; Theresa Nolan | Zendy; Yan Guo | Zendy; Steven L. Bernstein | Zendy

Open Access

A Single Intravitreal Injection of Ranibizumab Provides No Neuroprotection in a Nonhuman Primate Model of Moderate-to-Severe Nonarteritic Anterior Ischemic Optic Neuropathy

Author(s) -

Neil R. Miller,

Mary A. Johnson,

Theresa Nolan,

Yan Guo,

Steven L. Bernstein

Publication year - 2015

Publication title -

investigative ophthalmology and visual science

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.935

H-Index - 218

eISSN - 1552-5783

pISSN - 0146-0404

DOI - 10.1167/iovs.15-18015

Subject(s) - medicine , ranibizumab , neuroprotection , ophthalmology , anterior ischemic optic neuropathy , optic neuropathy , optic nerve , anesthesia , surgery , pharmacology , bevacizumab , chemotherapy

Ranibizumab, a vascular endothelial growth factor-antagonist, is said to be neuroprotective when injected intravitreally in patients with nonarteritic anterior ischemic optic neuropathy (NAION). We evaluated the efficacy of a single intravitreal (IVT) injection of ranibizumab in a nonhuman primate model of NAION (pNAION).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research